MedPath

The prevention and treatment effect of Shenlingbaizhu Powder from the perspective of the mechanism of the occurrence of ovarian hyperstimulation syndrome

Not Applicable
Recruiting
Conditions
Ovarian hyperstimulation syndrome
Registration Number
ITMCTR2200005791
Lead Sponsor
Guangdong Provincial Hospital of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

? Patients who may develop OHSS and meet the TCM syndrome differentiation criteria of deficiency of spleen and kidney were evaluated during COH;
? For ivF-ET patients aged 20-38 years, ovulation induction is suitable for fresh embryo transfer.
? Patients who signed informed consent and agreed to participate in the clinical trial with good compliance.
If the inclusion criteria above are not met, the patient cannot be included.

Exclusion Criteria

? Those who have taken similar drug treatment recently and whose efficacy is difficult to judge, or have a history of drug or alcohol abuse.
? Do not want to cooperate (such as not according to the provisions of the drug and affect the curative effect of qiao break) and mental illness, cognitive disorders.
? Emergency measures must be taken if symptoms worsen.
? Allergic constitution or allergic to a certain component of the drug used in the clinical trial.
? Those who are participating in clinical trials of other drugs.
? Failing to sign the informed consent.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
vascular endothelial growth factor;inflammatory factor;
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath